Global Rheumatology Therapeutics Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

Description

List of Tables

The global demand for Rheumatology Therapeutics Market is presumed to reach the market size of nearly USD 65.11 Billion by 2032 from USD 49.21 Billion in 2023 with a CAGR of 3.16% under the study period 2024 - 2032.

Rheumatology therapeutics refers to medications and treatments for managing and treating rheumatic diseases, encompassing autoimmune, inflammatory, and degenerative conditions affecting the joints, muscles, bones, and connective tissues. These therapeutics aim to alleviate pain, inflammation, stiffness, and joint damage, slow disease progression, improve physical function, and improve the standard of living for patients with rheumatic disorders.

MARKET DYNAMICS

The rising incidence of rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), osteoarthritis (OA), and other autoimmune and inflammatory conditions drives the demand for rheumatology therapeutics as patients seek effective treatments that alleviate symptoms, slow disease progression, and enhance the quality of life. With aging populations, genetic predisposition, and environmental factors contributing to the global burden of rheumatic diseases, there is a growing need for innovative therapeutics that target underlying disease mechanisms, modulate immune responses, and restore tissue homeostasis in affected individuals.

Additionally, advancements in biopharmaceutical research, immunology, and molecular biology enable the development of novel biologics, small molecule inhibitors, and targeted therapies that offer improved efficacy, safety, and tolerability profiles compared to conventional disease-modifying anti-rheumatic drugs (DMARDs) and nonsteroidal anti-inflammatory drugs (NSAIDs). Moreover, the increasing emphasis on precision medicine, biomarker discovery, and pharmacogenomics drives rheumatology therapeutics market innovation as pharmaceutical companies, biotech startups, and academic researchers collaborate to identify patient subgroups, stratify disease phenotypes, and develop personalized treatment algorithms that optimize therapeutic outcomes and minimize adverse effects.

Furthermore, the growing adoption of biosimilars, biosuperiors, and next-generation therapeutics in rheumatology drives market competition, pricing dynamics, and access to innovative treatments, creating opportunities and challenges for drug developers, healthcare providers, and patients. However, increasing competition from biosimilar alternatives and regulatory hurdles may challenge the rheumatology therapeutics market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of rheumatology therapeutics. The growth and trends of rheumatology therapeutics industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the rheumatology therapeutics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

Disease Modifying Anti-Rheumatic Drugs (Dmards) (Synthetic Disease Modifying Anti-Rheumatic Drugs, Biologic Disease Modifying Anti-Rheumatic Drugs)
Nonsteroidal Anti-Inflammatory Drugs (Nsaids)
Corticosteroids
Uric Acid Drugs
Others

By Disease Indication

Rheumatoid Arthritis
Osteoarthritis
Gout
Psoriatic Arthritis
Ankylosing Spondylitis
Others

By Route Of Administration

Parenteral Route
Oral Route
Topical

By Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Rheumatology Therapeutics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Rheumatology Therapeutics market include Merck & Co., Inc., AbbVie, Inc., Bristol-Myers Squibb Company, Pfizer, Inc., Takeda Pharmaceutical Company Limited, Amgen, Inc., Genentech, Inc., Novartis AG, Johnson & Johnson Innovative Medicine, F. Hoffmann-La Roche AG, Sanofi. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR112114346

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. RHEUMATOLOGY THERAPEUTICS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Class
- 3.7.2 Market Attractiveness Analysis By Disease Indication
- 3.7.3 Market Attractiveness Analysis By Route of Administration
- 3.7.4 Market Attractiveness Analysis By Distribution Channel
- 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET ANALYSIS BY DRUG CLASS

5.1. Overview By Drug Class
5.2. Historical and Forecast Data
5.3. Analysis By Drug Class
5.4. Disease Modifying Anti-rheumatic Drugs (DMARDs) (Synthetic Disease Modifying Anti-rheumatic Drugs, Biologic Disease Modifying Anti-rheumatic Drugs) Historic and Forecast Sales By Regions
5.5. Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Historic and Forecast Sales By Regions
5.6. Corticosteroids Historic and Forecast Sales By Regions
5.7. Uric Acid Drugs Historic and Forecast Sales By Regions
5.8. Others Historic and Forecast Sales By Regions

6. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET ANALYSIS BY DISEASE INDICATION

6.1. Overview By Disease Indication
6.2. Historical and Forecast Data
6.3. Analysis By Disease Indication
6.4. Rheumatoid Arthritis Historic and Forecast Sales By Regions
6.5. Osteoarthritis Historic and Forecast Sales By Regions
6.6. Gout Historic and Forecast Sales By Regions
6.7. Psoriatic Arthritis Historic and Forecast Sales By Regions
6.8. Ankylosing Spondylitis Historic and Forecast Sales By Regions
6.9. Others Historic and Forecast Sales By Regions

7. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

7.1. Overview By Route of Administration
7.2. Historical and Forecast Data
7.3. Analysis By Route of Administration
7.4. Parenteral Route Historic and Forecast Sales By Regions
7.5. Oral Route Historic and Forecast Sales By Regions
7.6. Topical Historic and Forecast Sales By Regions

8. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

8.1. Overview By Distribution Channel
8.2. Historical and Forecast Data
8.3. Analysis By Distribution Channel
8.4. Hospital Pharmacy Historic and Forecast Sales By Regions
8.5. Retail Pharmacy Historic and Forecast Sales By Regions
8.6. Online Pharmacy Historic and Forecast Sales By Regions

9. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET ANALYSIS BY GEOGRAPHY

9.1. Regional Outlook
9.2. Introduction
9.3. North America Sales Analysis
- 9.3.1 Overview, Historic and Forecast Data Sales Analysis
- 9.3.2 North America By Segment Sales Analysis
- 9.3.3 North America By Country Sales Analysis
- 9.3.4 United States Sales Analysis
- 9.3.5 Canada Sales Analysis
- 9.3.6 Mexico Sales Analysis
9.4. Europe Sales Analysis
- 9.4.1 Overview, Historic and Forecast Data Sales Analysis
- 9.4.2 Europe By Segment Sales Analysis
- 9.4.3 Europe By Country Sales Analysis
- 9.4.4 United Kingdom Sales Analysis
- 9.4.5 France Sales Analysis
- 9.4.6 Germany Sales Analysis
- 9.4.7 Italy Sales Analysis
- 9.4.8 Russia Sales Analysis
- 9.4.9 Rest Of Europe Sales Analysis
9.5. Asia Pacific Sales Analysis
- 9.5.1 Overview, Historic and Forecast Data Sales Analysis
- 9.5.2 Asia Pacific By Segment Sales Analysis
- 9.5.3 Asia Pacific By Country Sales Analysis
- 9.5.4 China Sales Analysis
- 9.5.5 India Sales Analysis
- 9.5.6 Japan Sales Analysis
- 9.5.7 South Korea Sales Analysis
- 9.5.8 Australia Sales Analysis
- 9.5.9 South East Asia Sales Analysis
- 9.5.10 Rest Of Asia Pacific Sales Analysis
9.6. Latin America Sales Analysis
- 9.6.1 Overview, Historic and Forecast Data Sales Analysis
- 9.6.2 Latin America By Segment Sales Analysis
- 9.6.3 Latin America By Country Sales Analysis
- 9.6.4 Brazil Sales Analysis
- 9.6.5 Argentina Sales Analysis
- 9.6.6 Peru Sales Analysis
- 9.6.7 Chile Sales Analysis
- 9.6.8 Rest of Latin America Sales Analysis
9.7. Middle East & Africa Sales Analysis
- 9.7.1 Overview, Historic and Forecast Data Sales Analysis
- 9.7.2 Middle East & Africa By Segment Sales Analysis
- 9.7.3 Middle East & Africa By Country Sales Analysis
- 9.7.4 Saudi Arabia Sales Analysis
- 9.7.5 UAE Sales Analysis
- 9.7.6 Israel Sales Analysis
- 9.7.7 South Africa Sales Analysis
- 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE RHEUMATOLOGY THERAPEUTICS COMPANIES

10.1. Rheumatology Therapeutics Market Competition
10.2. Partnership/Collaboration/Agreement
10.3. Merger And Acquisitions
10.4. New Product Launch
10.5. Other Developments

11. COMPANY PROFILES OF RHEUMATOLOGY THERAPEUTICS INDUSTRY

11.1. Top Companies Market Share Analysis
11.2. Market Concentration Rate
11.3. Merck & Co. Inc.
- 11.3.1 Company Overview
- 11.3.2 Company Revenue
- 11.3.3 Products
- 11.3.4 Recent Developments
11.4. AbbVie Inc.
- 11.4.1 Company Overview
- 11.4.2 Company Revenue
- 11.4.3 Products
- 11.4.4 Recent Developments
11.5. Bristol-Myers Squibb Company
- 11.5.1 Company Overview
- 11.5.2 Company Revenue
- 11.5.3 Products
- 11.5.4 Recent Developments
11.6. Pfizer Inc.
- 11.6.1 Company Overview
- 11.6.2 Company Revenue
- 11.6.3 Products
- 11.6.4 Recent Developments
11.7. Takeda Pharmaceutical Company Limited
- 11.7.1 Company Overview
- 11.7.2 Company Revenue
- 11.7.3 Products
- 11.7.4 Recent Developments
11.8. Amgen Inc.
- 11.8.1 Company Overview
- 11.8.2 Company Revenue
- 11.8.3 Products
- 11.8.4 Recent Developments
11.9. Genentech Inc.
- 11.9.1 Company Overview
- 11.9.2 Company Revenue
- 11.9.3 Products
- 11.9.4 Recent Developments
11.10. Novartis AG
- 11.10.1 Company Overview
- 11.10.2 Company Revenue
- 11.10.3 Products
- 11.10.4 Recent Developments
11.11. Johnson & Johnson Innovative Medicine
- 11.11.1 Company Overview
- 11.11.2 Company Revenue
- 11.11.3 Products
- 11.11.4 Recent Developments
11.12. F. Hoffmann-La Roche AG
- 11.12.1 Company Overview
- 11.12.2 Company Revenue
- 11.12.3 Products
- 11.12.4 Recent Developments
11.13. Sanofi
- 11.13.1 Company Overview
- 11.13.2 Company Revenue
- 11.13.3 Products
- 11.13.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies